https://ir.irulya.com/press_releases/quince-therapeutics-to-participate-in-september-2026-investor-conferences/ 2026-10-05T13:21:02+00:00 https://ir.irulya.com/press_releases/quince-therapeutics-to-host-virtual-kol-event-to-discuss-the-current-treatment-landscape-for-ph-ild-and-bos-and-the-role-for-lam-001-as-a-potential-therapeutic-option-on-september-28-2026/ 2026-10-05T13:21:44+00:00 https://ir.irulya.com/press_releases/quince-therapeutics-appoints-recognized-leaders-in-pulmonary-medicine-to-scientific-advisory-board/ 2026-10-05T13:23:59+00:00 https://ir.irulya.com/press_releases/quince-therapeutics-announces-clinically-meaningful-improvements-across-functional-hemodynamic-and-biomarker-measures-in-phase-2-study-in-pah-and-ph-ild/ 2026-10-05T15:21:12+00:00 https://ir.irulya.com/press_releases/quince-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-update/ 2026-10-05T15:27:11+00:00 https://ir.irulya.com/press_releases/quince-announces-acquisition-of-orphai-and-up-to-187-million-private-placement-to-advance-pulmonary-pipeline/ 2026-10-05T15:30:52+00:00 https://ir.irulya.com/press_releases/quince-therapeutics-relaunches-as-irulya-therapeutics-with-a-focus-on-the-clinical-development-of-lam-001-targeting-a-key-pathway-in-pulmonary-disease/ 2026-10-09T21:48:58+00:00